Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | FPR1 | P21462 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5171381 | 0.88 | MAPT (0.47) | MAPTSMN1; SMN2GABRA2GABRB2KLK7 | |
| SCHEMBL5171386 | 0.85 | MAPT (0.41) | MAPTSMN1; SMN2GABRA2GABRB2CFTR | |
| SCHEMBL14022801 | 0.85 | MEN1 (0.42) | MAPTSMN1; SMN2KMT2AMEN1POLB | |
| SCHEMBL4888122 | 0.83 | GABRA2 (0.61) | GABRA2GABRB2KMT2AKDM4ELMNA | |
| SCHEMBL14445096 | 0.80 | GABRA2 (0.52) | MAPTSMN1; SMN2GABRA2GABRB2CFTR | |
| SCHEMBL4894803 | 0.77 | POLB (0.40) | MAPTSMN1; SMN2KMT2AMEN1KDM4E | |
| SCHEMBL4887399 | 0.75 | MEN1 (0.45) | MAPTSMN1; SMN2GABRA2GABRB2KMT2A | |
| SCHEMBL4894806 | 0.75 | KCNH2 (0.40) | MAPTSMN1; SMN2 | |
| SCHEMBL4891104 | 0.75 | HDAC1 (0.41) | MAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5174504 | 0.73 | CNR1 (0.53) | MAPTSMN1; SMN2GABRA2GABRB2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242716-A1 | calcium channel modulator; [1-(4-Chloro-phenyl)-2-(4-fluoro-benzyl)-1H-imidazol-4-ylmethyl]-(4-fluoro-phenyl)-)-methyl-amine; analgesic, antidiabetic agent; angina, hypertension, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | SCION PHARMACEUTICALS, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242716-A1 | calcium channel modulator; [1-(4-Chloro-phenyl)-2-(4-fluoro-benzyl)-1H-imidazol-4-ylmethyl]-(4-fluoro-phenyl)-)-methyl-amine; analgesic, antidiabetic agent; angina, hypertension, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | SCION PHARMACEUTICALS, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20070281937-A1 | Ion Channel Modulators | SCION PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281937-A1 | Ion Channel Modulators | SCION PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281937-A1 | Ion Channel Modulators | CACNA1B, CACNA1C, TRPV1 | MAPT 490/4885SMN1; SMN2 661/4885GABRA2 267/4885 |
| US-20080242716-A1 | calcium channel modulator; [1-(4-Chloro-phenyl)-2-(4-fluoro-benzyl)-1H-imidazol-4-ylmethyl]-(4-fluoro-phenyl)-)-methyl-amine; analgesic, antidiabetic agent; angina, hypertension, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | CACNA1D, CACNA1C, TRPV1 | MAPT 425/4885SMN1; SMN2 436/4885GABRA2 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.